ERBB2 and carcinoma: In 2022, Okina et al reported that HER2‐positive ILBC especially in advanced stage had worse prognosis and shortened OS than HER2‐positive NST carcinomas and postulated the inconsistent administration of anti‐HER2 agents as a possible explanation [6].